The World Health Organization (WHO) global hepatitis strategy aims to reduce new infections by 90% and deaths by 65% by 2030. 1 In 2019, it was estimated that of the 58 million people infected worldwide, only 21% were diagnosed, and 62% of these treated with direct-acting antivirals. 1 Evidence of hepatitis C virus (HCV) transmission and emerging acute HCV infection among gay, bisexual, and other men who had sex with men (GBMSM), especially in human immunodeficiency virus (HIV)-infected individuals, had risen over the past two decades. 2 In 2018, European Centre for Disease Prevention and Control reported the prevalence in GBMSM at 4.7%. 3 Chemsex, recreational drug use for sex, was an important risk factor for primary infection and reinfection among GBMSM and the risk of transmission was increased with slamming (injecting drugs). 4 The SWEETIE study (HIV and sexually transmitted infection prevalence study in GBMSM and trans women sex workers) identified trans women (TW) as a vulnerable population with an HCV seroprevalence of 1.2%. 5 Research and engagement were urgently needed to integrate evidence-based interventions with HIV/sexually transmitted infections (STI) prevention in programmes that support screening and linkage to care. 6 An example was the Disfrutasin-C, a partnership with three nongovernmental organizations (NGOs) in Barcelona to inform about hepatitis C prevention.The WHO recommended the collection of dried blood spots (DBS) by finger prick due to ease of use and high sensitivity and specificity for HCV ribonucleic acid (RNA) detection. However, use was limited as many tests lacked regulatory approval. 7 The WHO had also recently published the first self-testing and self-sampling guidelines for HCV to expand access to screening. 7 Digital technologies to deliver information and sexual health interventions (sexual e-health) were increasingly used. A recent study in Amsterdam demonstrated that DBS self-sampling was feasible without compromising the sensitivity of HCV RNA detection and concluded that such intervention was a practical solution to improve access to testing for at-risk GBMSM. 8,9 To our knowledge, no online self-sampling intervention for screening for HCV viremic infection by viral RNA detection was performed in Spain. Might there be a need for innovative approaches to improve